Every material Form 8-K Sanara MedTech Inc. has filed with the SEC since September 30, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Sanara MedTech said it sold all assets of its wholly owned subsidiary Tissue Health Plus, LLC, including its business software products and related intellectual property, to an unrelated third party on October 6, 2026. The company received a purchase price of approximately $2,000,000 and certain earnout rights. The filing gives no revenue, profit, or segment figures for the business, so its effect on overall results cannot be assessed from this document.
Asset sale of Tissue Health Plus, LLC completed on October 6, 2026
Purchase price of approximately $2,000,000 paid to the company
Company also received certain earnout rights, with terms not described in the filing
Filed under Item 7.01 Regulation FD Disclosure on October 29, 2026
On October 15, 2026, Sanara MedTech and MiMedx each received a Second Request from the Federal Trade Commission as part of its review of the proposed merger in which Sanara would become a wholly-owned subsidiary of MiMedx. Under the Hart-Scott-Rodino Act, the Second Request extends the waiting period until 30 days after the parties substantially comply, so closing is likely to take longer, and completion still depends on regulatory and other conditions.
FTC issued a Second Request to Sanara and MiMedx on October 15, 2026.
The Second Request extends the HSR Act waiting period until 30 days after substantial compliance, unless extended or terminated earlier.
Completion remains subject to HSR waiting period expiration and other closing conditions in the Merger Agreement.
The filing does not state a expected closing date or any financial figures for the deal.
Sanara MedTech shareholders approved the merger agreement with MiMedx Group at a special meeting on September 30, 2026, with 6,372,989 votes for and 1,944 against. Shareholders also approved, on an advisory basis, merger-related compensation for Sanara's named executive officers. The merger still depends on the expiration of the HSR Act waiting period and the satisfaction or waiver of other closing conditions.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Sanara MedTech Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →